(Q46596539)

English

Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study

scientific article published in January 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18479178

Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study (English)

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18479178

Alzheimer's disease

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Joshua Shua-Haim

1

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18479178

Juanita Smith

2

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18479178

Franck Picard

3

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18479178

Greg Sedek

4

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18479178

Sandeep Athalye

5

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18479178

Françoise Pommier

6

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18479178

Gilbert Lefèvre

7

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18479178

publication date

1 January 2008

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18479178

Clinical Drug Investigation

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18479178

28

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18479178

6

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18479178

361-374

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18479178

Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.2165%2F00044011-200828060-00004

21 January 2018

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

1 reference

https://api.crossref.org/works/10.2165%2F00044011-200828060-00004

21 January 2018

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

1 reference

https://api.crossref.org/works/10.2165%2F00044011-200828060-00004

21 January 2018

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

1 reference

https://api.crossref.org/works/10.2165%2F00044011-200828060-00004

21 January 2018

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

1 reference

https://api.crossref.org/works/10.2165%2F00044011-200828060-00004

21 January 2018

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

1 reference

https://api.crossref.org/works/10.2165%2F00044011-200828060-00004

21 January 2018

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

1 reference

https://api.crossref.org/works/10.2165%2F00044011-200828060-00004

21 January 2018

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.2165%2F00044011-200828060-00004

21 January 2018

Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18479178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18479178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18479178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18479178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/18479178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/18479178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type

1 reference

https://pubmed.ncbi.nlm.nih.gov/18479178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil

1 reference

https://pubmed.ncbi.nlm.nih.gov/18479178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/18479178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications

1 reference

https://pubmed.ncbi.nlm.nih.gov/18479178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists

1 reference

https://pubmed.ncbi.nlm.nih.gov/18479178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain

1 reference

https://pubmed.ncbi.nlm.nih.gov/18479178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18479178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

“Mini-mental state”

1 reference

https://pubmed.ncbi.nlm.nih.gov/18479178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism

1 reference

https://pubmed.ncbi.nlm.nih.gov/18479178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/18479178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines for managing Alzheimer's disease: part I. Assessment

1 reference

https://pubmed.ncbi.nlm.nih.gov/18479178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18479178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines for managing Alzheimer's disease: Part II. Treatment.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18479178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/18479178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society

1 reference

https://pubmed.ncbi.nlm.nih.gov/18479178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. American Psychiatric Association

1 reference

https://pubmed.ncbi.nlm.nih.gov/18479178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Memantine for dementia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18479178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18479178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/18479178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitative determination of rivastigmine and its major metabolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry

1 reference

https://pubmed.ncbi.nlm.nih.gov/18479178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/18479178

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00044011-200828060-00004

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18479178

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/18479178

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46596539&oldid=2143724907"